Literature DB >> 6253432

Synergy between cefotaxime, cefsulodin, azlocillin, mezlocillin and aminoglycosides against carbenicillin resistant or sensitive Pseudomonas aeruginosa.

E J Perea, M C Nogales, J Aznar, E Martin, M C Iglesias.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6253432     DOI: 10.1093/jac/6.4.471

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  7 in total

1.  Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method.

Authors:  H O Hallander; K Dornbusch; L Gezelius; K Jacobson; I Karlsson
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

Review 2.  Sisomicin, netilmicin and dibekacin. A review of their antibacterial activity and therapeutic use.

Authors:  P Noone
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

3.  [Cefsulodin in the treatment of Pseudomonas meningitis].

Authors:  O Brückner; H Collmann; M Trautmann
Journal:  Infection       Date:  1983 Sep-Oct       Impact factor: 3.553

4.  Cefotaxime plus amikacin as empiric therapy in the treatment of febrile episodes in neutropenic patients with hematologic malignancies.

Authors:  P Martino; M Venditti; M C Petti; F Mandelli; P Serra
Journal:  Infection       Date:  1985 May-Jun       Impact factor: 3.553

Review 5.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 6.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546

7.  In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains.

Authors:  Devrim Dundar; Metin Otkun
Journal:  Yonsei Med J       Date:  2009-12-29       Impact factor: 2.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.